CSBio CSBio

X
[{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai and FUJI YAKUHIN Conclude License Agreement","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Fuji Yakuhin"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion\u2122 Targeting Severe Osteoarthritis of the Knee (OAK)","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ampio Pharmaceuticals"},{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"TLC BioSciences"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Paradigm Biopharmaceuticals"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Endo International","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$30.0 million","newsHeadline":"Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Taiwan Liposome Company"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gr\u00fcnenthal Starts Phase III Trials for Resiniferatoxin in Osteoarthritis-Related Pain","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Grunenthal"},{"orgOrder":0,"company":"LG Chem","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"$95.5 million","upfrontCash":"$10.0 million","newsHeadline":"Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"LG Chem"},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart\u00ae","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Ocugen"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"$670.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal to License Osteoarthritis Pain Treatment to Shionogi in Japan in Deal of up to > $ 500 Million","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Grunenthal"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Selecta Biosciences"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$705.0 million","upfrontCash":"$75.0 million","newsHeadline":"Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Selecta Biosciences"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Sobi will transition the manufacturing and development rights of ImmTOR for SEL-212 to Sobi. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in development for chronic refractory gout.

            Lead Product(s): Pegadricase,ImmTOR

            Therapeutic Area: Rheumatology Product Name: SEL-212

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Swedish Orphan Biovitrum AB

            Deal Size: $705.0 million Upfront Cash: $75.0 million

            Deal Type: Licensing Agreement October 31, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SEL-212 (combination of ImmTOR immune tolerance platform and pegadricase) is designed to reduce serum urate levels in people with chronic refractory gout, potentially reducing harmful tissue urate deposits which causes debilitating gout flares and joint deformity.

            Lead Product(s): SEL-037,SEL-110

            Therapeutic Area: Rheumatology Product Name: SEL-212

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ocugen’s proposed control and overall design for the Phase 3 study of NeoCart®, a regenerative cell therapy for the repair of full-thickness lesions of the knee cartilage in adults.

            Lead Product(s): Autologous Cartilagenous Tissue

            Therapeutic Area: Rheumatology Product Name: NeoCart

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.

            Lead Product(s): Tigulixostat

            Therapeutic Area: Rheumatology Product Name: LC350189

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Innovent Biologics

            Deal Size: $95.5 million Upfront Cash: $10.0 million

            Deal Type: Collaboration December 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis.

            Lead Product(s): Resiniferatoxin

            Therapeutic Area: Rheumatology Product Name: RTX

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 18, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX (resiniferatoxin) to Shionogi will be carried out exclusively by Grünenthal.

            Lead Product(s): Resiniferatoxin

            Therapeutic Area: Rheumatology Product Name: RTX

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Shionogi

            Deal Size: $670.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 04, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, TLC will primarily be responsible for the development of the product TLC599 (Dexamethasone Sodium Phosphate) and EVL will primarily be responsible for obtaining regulatory approval and commercialization of the product in the United States.

            Lead Product(s): Dexamethasone Sodium Phosphate

            Therapeutic Area: Rheumatology Product Name: TLC599

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Endo International

            Deal Size: $140.0 million Upfront Cash: $30.0 million

            Deal Type: Agreement June 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The purpose of the study is to measure the change in pain and function with subcutaneous injections of Zilosul (Pentosan Polysulfate Sodium) compared with subcutaneous injections of placebo in participants with kOA pain.

            Lead Product(s): Pentosan Polysulfate Sodium

            Therapeutic Area: Rheumatology Product Name: Zilosul

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Results showed that TLC599 (Dexamethasone Sodium Phosphate), a proprietary BioSeizer, demonstrated statistically significantly greater reduction in WOMAC pain and function as well as VAS scores compared to placebo through 24 weeks.

            Lead Product(s): Dexamethasone Sodium Phosphate

            Therapeutic Area: Rheumatology Product Name: TLC599

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ampion, a novel biologic drug containing a blood-derived cyclized peptide, demonstrated a statistically significant reduction in pain and trended favorably toward improvement in function versus saline control, retained more than 85% power to evaluate improvements in pain.

            Lead Product(s): Aspartyl-alanyl-diketopiperazine

            Therapeutic Area: Rheumatology Product Name: Ampion

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 02, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY